Man muss CALY schon zugestehen, dass im letzten halben Jahr eine Menge positive Dinge generiert wurden und mit dieser Basis haben die jetzt eine echte Zukunft.
Recent Highlights
During the second half of 2002 and in first part of 2003,
Calypte`s management team has moved forward with its objective to
advance sales growth by increasing product distribution and gaining
further acceptance in the marketplace. Recent highlights include:
-- Achieved sequential-quarterly revenue growth of 64% from
$493,000 to $809,000 in the fourth quarter.
-- As announced today, added Planned Parenthood Golden Gate to
the growing list of customers utilizing Calypte`s urine HIV-1
tests. As one of the larger Planned Parenthood affiliates,
this relationship represents an excellent opportunity to
demonstrate the benefits of urine testing to other Planned
Parenthood chapters and similar organizations.
-- Qualified for distribution in the state of California by
PathNet Esoteric Laboratory Institute, which specializes in
pathology, cytopathology and amplified esoteric sexually
transmitted disease (STD) testing for numerous women`s
healthcare providers. Calypte and PathNet intend to work
together to develop and implement outreach programs to notify
PathNet`s clients and other healthcare providers about the
test availability.
-- Received its first and second commercial orders from its
Chinese distributor for a total of over 260,000 tests. The
first order for 100,000 tests was received in October and
shipped in December and the second order for 160,000 tests was
received in January 2003, sooner than anticipated, and will be
shipped in the next several weeks.
-- Executed a Memorandum of Understanding with the Safe Blood for
Africa Foundation to market and distribute Calypte`s
urine-based HIV-1 antibody tests and Serum Western Blot tests
in sub-Saharan Africa. The tests are to be used as blood donor
pre-screening tools in Safe Blood for Africa Foundation`s
mission to help prevent the spread of HIV/AIDS throughout 34
countries in sub-Saharan Africa.
-- Joined the Community Healthcare Network`s (CHN) menu of
testing services. CHN, a not-for-profit organization, oversees
a network of nine health care centers and three mobile vans,
which reach over 60,000 individuals and their families in New
York City annually.
-- The U.S. Food and Drug Administration (FDA) eliminated the
requirement for lot release testing for the Calypte HIV-1
Urine EIA, as the result of a demonstrated multi-year history
of successful product manufacture. Elimination of the FDA lot
release testing is expected to reduce the production-to-market
time by two to eight weeks and decrease associated production
costs without sacrificing any product quality. A similar
elimination of FDA lot release testing for the Cambridge
Biotech HIV-1 Urine Western Blot is also being sought by the
company.
-- Gained recognition for Calypte`s test in a study led by Johns
Hopkins University that concluded urine-based HIV screening
can be an effective tool for identifying and treating infected
persons in high-prevalence inner city communities, and leads
to increased voluntary HIV testing versus testing for HIV with
blood samples. The test was published in the December 2002
JAIDS Journal of Acquired Immune Deficiency Syndromes.
-- Increased government relations expertise by hiring Dr. Richard
George, a CDC and HIV veteran, to spearhead global programs to
increase awareness of the importance of HIV testing, highlight
the benefits of urine-based testing, develop HIV testing
programs and secure capital to fund programs with public
sector and government-sponsored agencies.
-- Appointed Ms. Dian Harrison, CEO of Planned Parenthood Golden
Gate Chapter, to the company`s Board of Directors effective
February 24, 2003. The company intends to utilize Ms.
Harrison`s experience educating and administering care in
reproductive and general health issues. |
Thread abonnieren
